Leave Your Message

Nnukwu ọrịa leukemia Lymphoblastic (T-ALL) -06

Onye ọrịa: Xiaohong

okike: Nwoke

Afọ: 2 afọ

Obodo: Chinese

Nchọpụta nchọpụtaNnukwu ọrịa leukemia Lymphoblastic (T-ALL)

    Onye ọrịa ụmụaka dị afọ 2 nwere T-ALL na-enweta mgbaghara mgbe ọgwụgwọ CAR-T na-esochi ihe karịrị agba iri nke chemotherapy siri ike.


    Xiaohong dị afọ abụọ si Zhejiang nwere ọrịa leukemia n'oge okpomọkụ gara aga. Mgbe ihe karịrị otu afọ ọgwụgwọ gasịrị, cytometry eruba achọpụtala nlọghachi azụ, na-eduga ezinụlọ ka ha chọọ ọgwụ mgbochi ọrịa CAR-T na ụlọ ọgwụ Lu Daopei.


    N'August 9, 2020, a nabatara Xiaohong n'ụlọ ọgwụ ụmụaka n'ihi "ahụ ọkụ ụbọchị atọ." Nyocha nke ụmị ọkpụkpụ MICM chọpụtara nnukwu ọrịa leukemia lymphoblastic (T-ALL). Mgbe otu usoro ọgwụgwọ chemotherapy gasịrị, mpụta ụmị ọkpụkpụ gosipụtara mgbaghara zuru oke, na cytometry eruba achọpụtara na ọ nweghị mkpụrụ ndụ akabeghị aka. Chemotherapy kpụ ọkụ n'ọnụ sochiri ihe ọmụmụ iri na otu mere ka mgbaghara nke ụmị ọkpụkpụ zuru oke.


    Na Septemba 3, 2021, mwepu ụmị ọkpụkpụ na-esochi gosipụtara mgbaghara zuru oke na morphology, mana cytometry na-asọpụta kpughere 1.85% mkpụrụ ndụ akabeghị aka. N'ịchọ ọgwụgwọ ọzọ, a nabatara Xiaohong n'ụlọ ọgwụ Yanda Lu Daopei na Septemba 24. Mgbe a na-anabata ya, ọkpụkpụ ọkpụkpụ ọkpụkpụ ka na-agbaghara kpamkpam, ma immunophenotyping gosipụtara 0.10% malignant na-eto eto T lymphocytes.


    N'ịtụle afọ ndụ Xiaohong na nnọgidesi ike nke ọrịa ahụ n'agbanyeghị ihe karịrị agba iri nke chemotherapy kpụ ọkụ n'ọnụ, ndị otu ahụike nọ na ngalaba nke abụọ nke ngalaba hematology kpebiri na Xiaohong nwere ike debanye aha na CD7 CAR-T ụlọ ọgwụ.


    Na Septemba 30, 2021, achịkọtara mkpụrụ ndụ ọbara n'akụkụ maka ọdịbendị cell CAR-T. N'October 10, Xiaohong nwetara FC usoro ọgwụgwọ chemotherapy. N'October 13, mgbami ụmị ọkpụkpụ gosipụtara ihe na-erughị 5% mgbawa na morphology, na cytometry na-asọpụta gosiri 0.37% mkpụrụ ndụ T na-eto eto. N'October 15, eweghachiri sel CD7 CAR-T.


    Na Jenụwarị 3 (ụbọchị 20 ka ọ gafechara reinfusion), ụmị ọkpụkpụ gosipụtara mgbaghara zuru oke na morphology, na-enweghị mkpụrụ ndụ akabeghị aka nke cytometry na-asọpụta achọpụtara. Ọnọdụ Xiaohong ka kwụsiri ike, ma ebugharịla ya na ngalaba ntụgharị maka ịkwadebe maka transplant cell hematopoietic allogeneic.


    Xiaohong erubeghị otu afọ mgbe ọ dara ọrịa wee die ihe karịrị otu afọ ọgwụgwọ ọgwụ. Njikọ na-aga nke ọma na ntụgharị mgbe ọgwụgwọ CD7 CAR-T gasịrị enyela ngwa ọgụ dị ike iji merie ọrịa ahụ kpamkpam.

    4mm3

    Kemgbe July 2015, ụlọ ọgwụ Lu Daopei amalitela nnwale ụlọ ọgwụ nke CAR AT cell therapy na ọrịa ọbara. Dị ka otu n'ime nkeji mbụ ịmalite ọgwụgwọ cell CAR-T na China, ndị ọrịa 1342 abanyela na ikpe ahụ ruo ugbu a, na data ụlọ ọgwụ na-egosi arụmọrụ dị ukwuu na nchekwa nchekwa. CD7 bụ 40 kDa glycoprotein nke ezinụlọ superfamily immunoglobulin, CD7 nkịtị na-egosipụtakarị na sel T na sel NK yana n'oge mmalite nke ọdịiche nke mkpụrụ ndụ T, B na sel myeloid, ma nwee ike rụọ ọrụ dị ka onye na-anata ego. Mmekọrịta dị n'etiti T na B lymphocytes n'oge mmepe lymphocyte. CD7 bụ ihe nrịbama kwụsiri ike n'elu sel T ma a na-enyochakwa ya ugbu a dị ka ebumnuche ọhụụ na ọgwụgwọ cell CAR T maka ọrịa hematological. N'oge na-adịbeghị anya, na ngalaba nke abụọ nke Ngalaba Hematology nke Ụlọ Ọgwụ Ludaopei, ndị ọrịa 4 nwere ọnọdụ mgbagwoju anya enwetawo nsonaazụ doro anya mgbe ọgwụgwọ CD7 CAR-T gasịrị.

    nkọwa2

    Fill out my online form.